Physician profile
Diego Echeverri
NPI 1053308338
$2,490.52
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $48.03 · 2021: $335 · 2022: $643 · 2023: $317 · 2024: $453 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.07 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $323.62 | 2021-2025 | |
| Vifor Pharma, INC. | $314.26 | 2020-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $284.10 | 2022-2025 | Tarpeyo |
| Amgen INC. | $238.70 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $212.44 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $100.26 | 2019-2023 | Jynarque |
| Horizon Therapeutics Plc | $89.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $76.58 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $66.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $59.85 | 2020-2024 | |
| Opko Pharmaceuticals, LLC | $57.85 | 2019-2024 | Rayaldee |
| Mallinckrodt Enterprises LLC | $47.71 | 2019 | |
| Nxstage Medical, INC. | $46.49 | 2024 | |
| Ardelyx, INC. | $43.33 | 2024-2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $34.50 | 2019 | |
| Novo Nordisk INC | $26.56 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $21.01 | 2021 | |
| Genzyme Corporation | $15.08 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Echeverri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.